(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/132200 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *C07D 471/04* (2006.01)
A61K 31/4745 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/010065

(22) International Filing Date:
15 December 2021 (15.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/125,776	15 December 2020 (15.12.2020)	US
63/159,868	11 March 2021 (11.03.2021)	US
63/164,338	22 March 2021 (22.03.2021)	US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US]; 3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **WANG, Xiaolun**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **LAWSON, John David**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **MARX, Matthew Arnold**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **SMITH, Christopher Ronald**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US). **KULYK, Svitlana**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark V.**; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2022/132200 A1

(54) Title: AZAQUINAZOLINE PAN-KRAS INHIBITORS

(57) Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.